Accidental clozapine intoxication in a toddler: Clinical and pharmacokinetic lessons learnt

Clinic and Polyclinic for Pediatrics and Adolescent Medicine, Carl Gustav Carus University, Dresden National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA Institute of Forensic Medicine, University Medical Center, Freiburg Poison Information Center VIZ-Freiburg, University Medical Center, Freiburg, Germany.
Journal of Clinical Pharmacy and Therapeutics (Impact Factor: 1.67). 11/2012; 38(2). DOI: 10.1111/jcpt.12022
Source: PubMed


What is known and objective:
Clozapine, a second generation antipsychotic which is relatively safe in overdose, has been used as an effective treatment alternative to traditional antipsychotics. The therapeutic use in children remains controversial. However, in accordance with the increasing prescription in adults, the accidental ingestion in childhood becomes more frequent. We report the youngest case of accidental clozapine ingestion.

Case summary:
A 13-month-old girl presented with acute respiratory insufficiency and coma of unknown origin. The medical history, laboratory and radiological assessment did not link to aetiology until an almost spontaneous arousal after 22 h pointed towards intoxication. The initial standard drug screening using immunoassay had been negative. Hence, liquid chromatography mass spectrometry/mass spectrometry (LC-MS/MS) was performed, and clozapine was detected with a serum concentration of 736 ng/mL.

What is new and conclusion:
This case illustrates the diagnostic and forensic pitfalls in a coma of unknown origin due to the limits of toxicological screening immunoassays. LC-MS/MS analysis by an established method showed clozapine metabolites (norclozapine and clozapine-N-oxide) are detectable for longer period, especially in urine, when compared with clozapine. The clinical course is presented in unique correlation with plasma and urine concentrations of clozapine and its metabolites. The elimination pattern of clozapine in toddlers is similar to adults, and the toxic dose was found to be lower when compared with school-age children and adults.

Download full-text


Available from: Volker Auwärter,
  • [Show abstract] [Hide abstract]
    ABSTRACT: The inclusion interaction of sulfobutylether-β-cyclodextrin with clozapine was studied using flow injection chemiluminescence and molecular docking. By use of a homemade flow injection chemiluminescence model of lg[(I 0−I s)/I s] = lgK + nlg[C clozapine], the formation constant K, the stoichiometric ratio n, and thermodynamic parameters between sulfobutylether-β-cyclodextrin and clozapine were obtained. Results showed that the inclusion forming process of sulfobutylether-β-cyclodextrin/clozapine with a stoichiometric ratio of 1:1 was spontaneous through hydrophobic interaction. The molecular docking results showed that clozapine entered into the cavity of sulfobutylether-β-cyclodextrin with one hydrogen bond. Based on the good linear relationship of quenching of chemiluminescence intensity versus the logarithm of concentration between 0.07 and 50.0 ng mL−1, a flow injection chemiluminescence method for clozapine was established for the first time with a detection limit of 0.02 ng mL−1 (3σ). The proposed method was successfully applied for the determination of clozapine in spiked human urine and serum samples, with recoveries from 92.1–108.2% and relative standard deviations less than 2.7%.
    Instrumentation Science & Technology 01/2014; 42(1). DOI:10.1080/10739149.2013.834449 · 0.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In children and adolescents, the prevalence rate of mental illness is claimed to be as high as 10-20%. Effective pharmacological treatments are available for use in children, adolescents, and adults; however, most of what is known about the effects of these treatments has been confirmed in clinical studies involving adults only. Second generation antipsychotic drugs (SGAs) are the most common class of antipsychotic medication used in pediatric populations, and these drugs are increasingly being used for disorders other than psychosis. Many SGAs are routinely used in pediatric care, and the vast majority of use in this population is off label. Children, adolescents, and adults differ in age, weight, height, and metabolism, which may lead to pharmacokinetic differences in how drugs ultimately affect target tissues. The aim of this review is to summarize and evaluate the literature that investigated blood plasma levels of SGAs in youth. Plasma levels were assessed in relation to their administered dose, indication, and therapeutic range (if known). Studies were limited to those evaluating oral administration only. A systematic electronic database search for peer-reviewed articles published between 2000 and 2013 was conducted. Twenty-one articles were included in the review. Additional articles for discussion were also included throughout the article. The only SGA that may require routine therapeutic drug monitoring (TDM) in youth given the current body of research is clozapine. Highly variable results were seen in studies of aripiprazole, olanzapine, and risperidone, indicating that more research is needed on plasma levels with these drugs. Quetiapine maintained a similar profile to that found in adults, with no dosage adjustments or indications of TDM. TDM may be indicated in any circumstance in which cytochrome P450 inhibitors or inducers are coprescribed. Further research is required for establishing a sounder safety profile for SGA use in the pediatric population.
    Journal of child and adolescent psychopharmacology 03/2015; 25(3). DOI:10.1089/cap.2014.0044 · 2.93 Impact Factor